PURPOSE: To correlate changes in 2-deoxy-2-[18F]fluoro-d-glucose (18-FDG) positron emission tomography (PET) (18-FDG-PET) uptake with response and disease-free survival with combined modality neoadjuvant therapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: Charts were reviewed for consecutive patients with ultrasound-staged T3x to T4Nx or TxN1 rectal adenocarcinoma who underwent preoperative chemoradiation therapy at Fox Chase Cancer Center (FCCC) or Robert H. Lurie Comprehensive Cancer Center of Northwestern University with 18-FDG-PET scanning before and after combined-modality neoadjuvant chemoradiation therapy . The maximum standardized uptake value (SUV) was measured from the tumor before and 3 to 4 weeks after completion of chemoradiation therapy preoperatively. Logistic regression was used to analyze the association of pretreatment SUV, posttreatment SUV, and % SUV decrease on pathologic complete response (pCR), and a Cox model was fitted to analyze disease-free survival. RESULTS: A total of 53 patients (FCCC, n = 41, RLCCC, n = 12) underwent pre- and postchemoradiation PET scanning between September 2000 and June 2006. The pCR rate was 31%. Univariate analysis revealed that % SUV decrease showed a marginally trend in predicting pCR (p = 0.08). In the multivariable analysis, posttreatment SUV was shown a predictor of pCR (p = 0.07), but the test results did not reach statistical significance. None of the investigated variables were predictive of disease-free survival. CONCLUSIONS: A trend was observed for % SUV decrease and posttreatment SUV predicting pCR in patients with rectal cancer treated with preoperative chemoradiation therapy. Further prospective study with a larger sample size is warranted to better characterize the role of 18-FDG-PET for response prediction in patients with rectal cancer.
PURPOSE: To correlate changes in 2-deoxy-2-[18F]fluoro-d-glucose (18-FDG) positron emission tomography (PET) (18-FDG-PET) uptake with response and disease-free survival with combined modality neoadjuvant therapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: Charts were reviewed for consecutive patients with ultrasound-staged T3x to T4Nx or TxN1 rectal adenocarcinoma who underwent preoperative chemoradiation therapy at Fox Chase Cancer Center (FCCC) or Robert H. Lurie Comprehensive Cancer Center of Northwestern University with 18-FDG-PET scanning before and after combined-modality neoadjuvant chemoradiation therapy . The maximum standardized uptake value (SUV) was measured from the tumor before and 3 to 4 weeks after completion of chemoradiation therapy preoperatively. Logistic regression was used to analyze the association of pretreatment SUV, posttreatment SUV, and % SUV decrease on pathologic complete response (pCR), and a Cox model was fitted to analyze disease-free survival. RESULTS: A total of 53 patients (FCCC, n = 41, RLCCC, n = 12) underwent pre- and postchemoradiation PET scanning between September 2000 and June 2006. The pCR rate was 31%. Univariate analysis revealed that % SUV decrease showed a marginally trend in predicting pCR (p = 0.08). In the multivariable analysis, posttreatment SUV was shown a predictor of pCR (p = 0.07), but the test results did not reach statistical significance. None of the investigated variables were predictive of disease-free survival. CONCLUSIONS: A trend was observed for % SUV decrease and posttreatment SUV predicting pCR in patients with rectal cancer treated with preoperative chemoradiation therapy. Further prospective study with a larger sample size is warranted to better characterize the role of 18-FDG-PET for response prediction in patients with rectal cancer.
Authors: Harvey G Moore; Alicia E Gittleman; Bruce D Minsky; Douglas Wong; Philip B Paty; Martin Weiser; Larissa Temple; Leonard Saltz; Jinru Shia; Jose G Guillem Journal: Dis Colon Rectum Date: 2004-03 Impact factor: 4.585
Authors: J G Guillem; J Puig-La Calle; T Akhurst; S Tickoo; L Ruo; B D Minsky; M J Gollub; D S Klimstra; M Mazumdar; P B Paty; H Macapinlac; H Yeung; L Saltz; R D Finn; Y Erdi; J Humm; A M Cohen; S Larson Journal: Dis Colon Rectum Date: 2000-01 Impact factor: 4.585
Authors: Andre Konski; Mohan Doss; Barton Milestone; Oleh Haluszka; Alexandra Hanlon; Gary Freedman; Lee Adler Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Carlo Capirci; Domenico Rubello; Franca Chierichetti; Giorgio Crepaldi; Angelo Carpi; Andrea Nicolini; Giovanni Mandoliti; Cesare Polico Journal: Biomed Pharmacother Date: 2004-10 Impact factor: 6.529
Authors: Felipe A Calvo; Marta Domper; Raúl Matute; Raúl Martínez-Lázaro; José A Arranz; Manuel Desco; Emilio Alvarez; José Luis Carreras Journal: Int J Radiat Oncol Biol Phys Date: 2004-02-01 Impact factor: 7.038
Authors: Hinrich A Wieder; Björn L D M Brücher; Frank Zimmermann; Karen Becker; Florian Lordick; Ambros Beer; Markus Schwaiger; Ulrich Fink; Jörg Rüdiger Siewert; Hubert J Stein; Wolfgang A Weber Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Jose G Guillem; Harvey G Moore; Timothy Akhurst; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Bruce D Minsky; Leonard Saltz; W Douglas Wong; Steven Larson Journal: J Am Coll Surg Date: 2004-07 Impact factor: 6.113
Authors: Jong Wan Kim; Hyun Chul Kim; Ji Won Park; Sung Chan Park; Dae Kyung Sohn; Hyo Seong Choi; Dae Yong Kim; Hee Jin Chang; Ji Yeon Baek; Sun Young Kim; Seok Ki Kim; Jae Hwan Oh Journal: Int J Colorectal Dis Date: 2013-02-13 Impact factor: 2.571
Authors: R O Perez; A Habr-Gama; G P São Julião; P B Lynn; C Sabbagh; I Proscurshim; F G Campos; J Gama-Rodrigues; S C Nahas; C A Buchpiguel Journal: Tech Coloproctol Date: 2014-02-08 Impact factor: 3.781
Authors: Maka Kekelidze; Luigia D'Errico; Michele Pansini; Anthony Tyndall; Joachim Hohmann Journal: World J Gastroenterol Date: 2013-12-14 Impact factor: 5.742